Clinical trial Recruiting at 1 site Interventional Ages 18 to 48 Women only

Cord-blood PRP therapy to help thin or scarred uterine lining

Official title: CURENDO (Cord-blood Uterine Regeneration Endometrium): Platelet-rich Plasma Therapy Derived From Umbilical Cord Blood for the Treatment of Endometrial Pathologies (Asherman Syndrome / Endometrial Atrophy / Thin Endometrium)

Run by Fundación IVI · NCT07697924 · Data updated 2026-11-12

This study tests whether umbilical cord blood–derived platelet-rich plasma can improve the thickness and appearance of the endometrium in women with Asherman syndrome, endometrial atrophy, or a thin lining.

Quick facts

Study typeInterventional
Ages18 Years to 48 Years
SexWomen only
Enrollment35 (estimated)
SponsorFundación IVI
Academic / other
Locations1 site (Valencia)
StatusRecruiting
StartedDecember 18, 2025
Main results expectedDecember 2029
Study endsDecember 2029
Registry record updatedJuly 13, 2026
Trial IDNCT07697924 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Women aged 18–48 with BMI 18–35 and a thin or scarred endometrium (<5 mm) despite estrogen or confirmed Asherman syndrome.

Probably not a fit

Patients with non-endometrial causes of infertility or those who do not respond to the therapy may not experience benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study investigates the use of umbilical cord blood–derived platelet-rich plasma (hUC-PRP) injected into the uterine lining to improve endometrial thickness and pattern in women with endometrial pathologies. Building on prior pilot data, the study plans to enroll 35 participants who have persistent thin endometrium despite estrogen therapy or have Asherman syndrome. Eligible participants are women aged 18–48 with BMI 18–35, and endometrium <5 mm under treatment or confirmed Asherman syndrome, excluding active infections or other major contraindications. The intervention involves hysteroscopic administration of hUC-PRP, with outcomes focused on endometrial restoration and potential future fertility impact. The investigation is conducted under the Fundación IVI at IVI Valencia, with standard safety screening and follow-up procedures.

Why it matters

Potential benefit: If successful, participants could experience improved endometrial thickness and pattern, potentially supporting better chances of pregnancy in the future.

How similar studies have gone: Some prior studies suggest PRP approaches may help endometrial growth, but results vary and this cord blood–derived method is still exploratory.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* age between 18 and 48 years at the time of recruitment
* body mass index (BMI): ≥ 18 kg/m2 and ≤ 35 kg/m2
* endometrial thickness \< 5 mm despite estrogen administration according to each clinic's routine practice for 10 or more days and/or evidence of Asherman syndrome.

Exclusion Criteria:

* Active genital infection at the time of recruitment
* chronic endometritis
* known endometrial pathology
* psychiatric disorder that could hinder study follow-up
* positive results on viral safety testing (HBsAg, HBcAb, HCV, HIV-1, HIV-2, syphilis)
* presence of any syndrome or condition that, in the opinion of the principal investigator, could pose a risk to the study or to the patient
* any clinically significant abnormality detected during the recruitment process
* simultaneous participation in another clinical study that could affect the objectives of the present study, or prior participation in this same study.

Where it's running

  • IVI Valencia
    Valencia, Spain
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.